Impact of the new FIGO 2009 staging classification for vulvar cancer on prognosis and stage distribution

Tabbaa, Zaid M.; González, J.P.; Sznurkowski, Jacek Jan; Weaver, Amy L.; Mariani, Andrea; Cliby, William A.

doi:10.1016/j.ygyno.2012.06.005

Cited by 54 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, OS and disease-free survival for these patients approached those of patients with M0 disease with positive inguinal nodes (i.e., FIGO stage III disease) [14, 15]. …”

Section: Discussionmentioning

confidence: 99%

Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: Time to reconsider the FIGO staging system?

Thaker

Klopp

Jhingran

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

Objective To evaluate treatment outcomes for patients with vulvar cancer with grossly positive pelvic lymph nodes (PLNs). Methods From a database of 516 patients with vulvar cancer, we identified patients with grossly positive PLNs without distant metastasis at initial diagnosis. We identified 20 patients with grossly positive PLNs; inclusion criteria included PLN 1.5 cm or larger in short axis dimension on CT/MRI (n=11), FDG-avid PLN on PET/CT (n=3), or biopsy-proven PLN disease (n=6). Ten patients were treated with chemoradiation (CRT) therapy, 4 with RT alone, and 6 with various combinations of surgery, RT or CRT. Median follow-up time for patients who had not died of cancer was 47 months (range, 4-228 months). Results Mean primary vulvar tumor size was 6.4 cm; 12 patients presented with 2009 AJCC T2 and 8 with T3 disease. All patients had grossly positive inguinal nodes, and the mean inguinal nodal diameter was 2.8 cm. The 5-year overall survival and disease specific survival rates were 43% and 48%, respectively. Eleven patients had recurrences, some at multiple sites. There were 9 recurrences in the vulva, but no isolated nodal recurrences. Four patients developed distant metastasis within 6 months of starting radiation therapy. Conclusions Aggressive locoregional treatment can lead to favorable outcomes for many patients with grossly involved PLNs that is comparable to that of grossly involved inguinal nodes only. We recommend modification of the FIGO stage IVB classification to more accurately reflect the relatively favorable prognosis of patients with PLN involvement.

show abstract

“…Indeed, OS and disease-free survival for these patients approached those of patients with M0 disease with positive inguinal nodes (i.e., FIGO stage III disease) [14, 15]. …”

Section: Discussionmentioning

confidence: 99%

Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: Time to reconsider the FIGO staging system?

Thaker

Klopp

Jhingran

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Squamous cell carcinoma (SCC) represents the most common histologic type that comprises almost 90% of vulvar cancers (Del Pino et al, 2013). Patients with early stage vulvar SCC have a favorable prognosis and can be successfully treated by surgery with a 10-year diseasespecific survival of approximately 80-90% (Tabbaa et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

HPV Detection and Genotyping in Vulvar Squamous Cell Carcinoma in Northern Thailand

Siriaunkgul

Settakorn²,

Sukpan³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…20 The impact of this revised classification system has been examined. [23][24][25] The presentation of vulvar cancer can be widely varied. Most vulvar cancers are located in the labia majora, but other possible sites include the labia minora, clitoris, mons, or perineum.…”

Section: Diagnosis and Workupmentioning

confidence: 99%

Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Koh¹,

Greer²,

Abu‐Rustum³

et al. 2016

J Natl Compr Canc Netw

Self Cite

152

215

View full text Add to dashboard Cite

Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC. This manuscript discusses the recommendations outlined in the NCCN Guidelines for diagnosis, staging, treatment, and follow-up.

show abstract

Impact of the new FIGO 2009 staging classification for vulvar cancer on prognosis and stage distribution

Cited by 54 publications

References 21 publications

Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: Time to reconsider the FIGO staging system?

Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: Time to reconsider the FIGO staging system?

HPV Detection and Genotyping in Vulvar Squamous Cell Carcinoma in Northern Thailand

Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Contact Info

Product

Resources

About